Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tamsulosin | Experimental |
| |
| Alfuzosin | Experimental |
| |
| Doxazosin | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tamsulosin | Drug |
|
| |
| Alfuzosin |
| Measure | Description | Time Frame |
|---|---|---|
| Sum of changes from baseline in the mean pupil diameters | Baseline, 60 and 80 min after administration of phenylephrine (PE) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in mean diameter of both pupils | Baseline, 60 and 80 min after administration of phenylephrine (PE) | |
| Change from baseline in mean diameter of both pupils | one week after cessation of drug |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The following exclusion criteria are of special interest for this study:
Hypersensitivity to any alpha agonist, or to phenylephrine
Supine blood pressure at screening of systolic < 110 mmHg and diastolic < 60 mmHg
Ophthalmological criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
|
| Doxazosin | Drug |
|
|
| Placebo | Drug |
|
| Concentration of the analyte in plasma | Up to 29 days after first administration of α-antagonists |
| Number of participants with clinically significant changes in vital signs | Up to 8 days after last pupillometry |
| Number of participants with abnormal changes in clinical laboratory parameters | Up to 8 days after last pupillometry |
| Number of participants with Adverse Events | Up to 8 days after last pupillometry |
| Assessement of global tolerability by investigator on a 4 point scale | 8 days after last pupillometry |
| ID | Term |
|---|---|
| D000077409 | Tamsulosin |
| C443986 | AlnA protein, Acinetobacter radioresistens |
| C047638 | alfuzosin |
| D017292 | Doxazosin |
| ID | Term |
|---|---|
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011224 | Prazosin |
| D011799 | Quinazolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided